Pharmaceutical companies explore AI to speed up drug discovery
Major pharmaceutical companies are closely following advances by companies specialized in artificial intelligence and evaluating applications capable of analyzing large volumes of biological data. The expectation is that these systems will help select promising molecules, anticipate properties and reduce testing stages that traditionally require long research periods. The technology does not eliminate the need for laboratory trials, clinical studies and regulatory controls: algorithm results must be verified before becoming treatments for patients.
In 30 seconds
- Pharmaceutical firms are evaluating AI tools to analyze large volumes of biological data
- The goal is to select promising molecules and anticipate properties more quickly
- AI does not replace laboratory trials, clinical studies or regulatory controls
IASummary generated by artificial intelligence from a story by Diario del Sur. It may contain errors: the original source prevails.



Comments
Be respectful. Comments reported by several people are hidden until a moderator reviews them.
You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.